GlassScriptPhysician profile
Faiza Manji
NPI 1740697192
$5,928.63
in general payments reported to CMS, 2019-2025
53 companies · $3,195 in 2025
The $3,195 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2023: $182 · 2024: $2,443 · 2025: $3,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,820.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $658.15 | 2024-2025 | |
| Astellas Pharma US INC | $494.97 | 2024-2025 | Vyloy, Xospata, Padcev |
| Novartis Pharmaceuticals Corporation | $453.31 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $390.29 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $327.97 | 2023-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $258.13 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $234.81 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $220.60 | 2024-2025 | Rybrevant, Tecvayli, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $193.67 | 2024-2025 | Fruzaqla |
| Abbvie INC. | $162.88 | 2024-2025 | |
| Genzyme Corporation | $152.88 | 2024-2025 | |
| Lilly USA, LLC | $142.79 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $137.54 | 2024-2025 | Reblozyl, Opdualag |
| Genentech USA, INC. | $132.45 | 2024-2025 | Tecentriq, Polivy, Alecensa |
| Taiho Oncology, INC. | $131.55 | 2024-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $121.61 | 2024-2025 | Orserdu |
| Incyte Corporation | $118.06 | 2024-2025 | Monjuvi, Zynyz, Jakafi |
| Alexion Pharmaceuticals, INC. | $114.54 | 2024-2025 | Ultomiris |
| Array Biopharma INC | $102.03 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Astrazeneca Pharmaceuticals LP | $83.05 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Daiichi Sankyo INC. | $80.22 | 2024-2025 | Enhertu, Datroway |
| Eisai INC. | $79.68 | 2024 | |
| Blueprint Medicines Corporation | $79.51 | 2024-2025 | Ayvakit |
| Tersera Therapeutics LLC | $71.57 | 2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $68.68 | 2024-2025 | Cosela, Monoferric |
| Sobi, INC | $62.29 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.61 | 2024 | |
| Sumitomo Pharma America, INC. | $54.77 | 2024-2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $52.28 | 2024-2025 | Libtayo |
| Beone Medicines USA, INC. | $51.33 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $47.34 | 2023 | Imbruvica |
| Beigene USA, INC. | $45.20 | 2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $43.09 | 2024-2025 | |
| Legend Biotech USA INC. | $41.01 | 2024-2025 | Carvykti |
| Kite Pharma, INC. | $40.83 | 2019-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $39.93 | 2024 | |
| Pharmaessentia USA Corporation | $36.35 | 2024-2025 | Besremi |
| Kyowa Kirin, INC. | $28.17 | 2025 | |
| Emmaus Medical, INC. | $27.61 | 2024 | Endari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.29 | 2019 | |
| Immunocore Limited | $24.66 | 2025 | Kimmtrak |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Exact Sciences Corporation | $24.20 | 2025 | Cologuard Collection Kit |
| Accord Healthcare, INC. | $23.02 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $23.00 | 2025 | Onivyde |
| Servier Pharmaceuticals LLC | $22.02 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.20 | 2025 | Givlaari |
| Emd Serono, INC. | $19.11 | 2024 | |
| Exelixis INC. | $18.98 | 2024 | Cabometyx |
| Geron Corporation | $18.54 | 2025 | Rytelo |
| Novocure INC. | $15.05 | 2025 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $14.51 | 2025 | Qinlock, Romvimza |
| Seagen INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Manji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.